Company intelligence / Profile preview

Sprout Pharmaceuticals

Raleigh, North Carolina, United Statessproutpharmaceuticals.com ↗

Ownership: Private
Employees: ~31
Development stage: Commercial

Overview

Sprout Pharmaceuticals developed Addyi (flibanserin), the first FDA-approved drug for treating hypoactive sexual desire disorder in premenopausal women. The company achieved FDA approval and commercial launch but has faced ongoing controversy regarding efficacy and marketing practices. Addyi remains the company's flagship product.

Therapeutic areas: Women's Health
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

flibanserin

Approved

Partnerships

No major current pharmaceutical partnerships disclosed; previously acquired by Valeant Pharmaceuticals International [now Bausch Health], which was a key relationship during that period.

Beyond the preview

Go deeper on Sprout Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sprout Pharmaceuticals.

Explore the full profile